3-(2-naphthoyl)-7-benzoylindolizine-1-carboxylic acid | 1454597-29-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-(2-naphthoyl)-7-benzoylindolizine-1-carboxylic acid
• CAS: 1454597-29-5
• 化学式: C₂₇H₁₇NO₄
• 分子量: 419.436
• InChiKey: UPUDFFSHRPBWBX-UHFFFAOYSA-N

物化性质

• 密度：
  1.29±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.25
• 重原子数：
  32.0
• 可旋转键数：
  5.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.85
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  3-(2-naphthoyl)-7-benzoylindolizine-1-carboxylic acid 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 56.0h， 生成 N-[2-[2-[2-[[2-[2-[2-[2-[5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]ethoxy]ethoxy]ethoxy]-4-[3-(trifluoromethyl)diazirin-3-yl]benzoyl]amino]ethoxy]ethoxy]ethyl]-7-benzoyl-3-(naphthalene-2-carbonyl)indolizine-1-carboxamide
  参考文献：
  名称：

  Indolizine Derivatives as HIV-1 VIF-ElonginC Interaction Inhibitors

  摘要：

  Compound 1 (VEC‐5) was identified as a potent small‐molecular HIV‐1 viron infectivity factor inhibitor that targets the viron infectivity factor–ElonginC interaction. A structure–activity relationship study was carried out to develop compounds with improved efficacy against HIV‐1 and 49 indolizine derivatives of three categories were designed and synthesized. We found that five compounds exhibited promising anti‐HIV‐1 activity, and the most active compound 2g had an IC50 value of 11.0 μm. These results provide new information to develop highly potent small‐molecule HIV‐1 viron infectivity factor inhibitors.

  DOI：

  10.1111/cbdd.12119
• 作为产物：
  描述：

  4-苯甲酰吡啶 在 potassium carbonate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙酸乙酯 、 乙腈 为溶剂， 反应 77.5h， 生成 3-(2-naphthoyl)-7-benzoylindolizine-1-carboxylic acid
  参考文献：
  名称：

  Indolizine Derivatives as HIV-1 VIF-ElonginC Interaction Inhibitors

  摘要：

  Compound 1 (VEC‐5) was identified as a potent small‐molecular HIV‐1 viron infectivity factor inhibitor that targets the viron infectivity factor–ElonginC interaction. A structure–activity relationship study was carried out to develop compounds with improved efficacy against HIV‐1 and 49 indolizine derivatives of three categories were designed and synthesized. We found that five compounds exhibited promising anti‐HIV‐1 activity, and the most active compound 2g had an IC50 value of 11.0 μm. These results provide new information to develop highly potent small‐molecule HIV‐1 viron infectivity factor inhibitors.

  DOI：

  10.1111/cbdd.12119